Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results
Rafael Holdings reported its Q3 fiscal 2026 financial results, highlighting the completion of the last patient last visit in its pivotal Phase 3 trial for Trappsol® Cyclo™, a treatment for Niemann-Pick Disease Type C1 (NPC). The company plans to submit a New Drug Application (NDA) in the second half of 2026, aiming to enter the commercial stage. Fi…